

# The Role of Helicobacter Pylori Infection in Gastric Carcinoma Pathogenesis

Ramakant Bhosale<sup>1</sup> and Dr. Nagendra Pratap Mishra<sup>2</sup>

Research Scholar, Department of Biochemistry<sup>1</sup>

Research Guide, Department of Biochemistry<sup>2</sup>

Sunrise University, Alwar, Rajasthan, India

**Abstract:** Gastric carcinoma is one of the prevalent types of cancer globally with a notable morbidity and mortality rate. *Helicobacter pylori* (*H. pylori*) infection has been established as a significant risk factor for gastric carcinoma. This paper reviews current literature on the role of *H. pylori* infection in the pathogenesis of gastric carcinoma, exploring molecular mechanisms and clinical implications. Furthermore, the paper discusses potential preventive and therapeutic strategies to combat gastric carcinoma associated with *H. pylori* infection.

**Keywords:** Prognostic Implications, Histopathology, Resection Margins

## REFERENCES

- [1]. Ferlay JSI, Ervik M, Dikshit R, et al. International Agency for Research on Cancer, Cancer Incidence, and Mortality Worldwide. Lyon, France: IARC CancerBase no. 11, 2013.
- [2]. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010;376:687–697.
- [3]. Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 2014;513:202–209.
- [4]. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—first American Cancer Society Award Lecture on cancer epidemiology and prevention. *Cancer Res* 1992;52:6735–6740.
- [5]. Almeida R, Silva E, Santos-Silva F, et al. Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas. *J Pathol* 2003;199:36–40.
- [6]. Goldenring JR, Nomura S. Differentiation of the gastric mucosa III. Animal models of oxyntic atrophy and metaplasia. *Am J Physiol Gastrointest Liver Physiol* 2006;291:G999–1004.
- [7]. Goldenring JR, Nam KT. Oxyntic atrophy, metaplasia, and gastric cancer. *Dev Diff Dis* 2010;96:117–131.
- [8]. Karin M. Inflammation and cancer: the long reach of Ras. *Nat Med* 2005;11:20–21.
- [9]. Eaton KA, Logan SM, Baker PE, et al. Helicobacter pylori with a truncated lipopolysaccharide O chain fails to induce gastritis in SCID mice injected with splenocytes from wild-type C57BL/6J mice. *Infect Immun* 2004; 72:3925–3931.
- [10]. Lochhead P, El-Omar EM. Gastric cancer. *Br Med Bull* 2008;85:87–100.
- [11]. Tsugane S, Sasazuki S. Diet and the risk of gastric cancer: review of epidemiological evidence. *Gastric Cancer* 2007;10:75–83.
- [12]. Noto JM, Gaddy JA, Lee JY, et al. Iron deficiency accelerates Helicobacter pylori-induced carcinogenesis in rodents and humans. *J Clin Invest* 2013;123:479–492.
- [13]. Iwakiri D TK. Epstein-Barr virus and gastric cancers. In: ES R, ed. Epstein-Barr virus. Norfolk, VA: Caister Academic Press, 2005:157–169.
- [14]. Murphy G, Pfeiffer R, Camargo MC, et al. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. *Gastroenterology* 2009;137:824–833.
- [15]. Peleteiro B, Bastos A, Ferro A, et al. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. *Dig Dis Sci* 2014; 59:1698–1709.

- [16]. Odenbreit S, Puls J, Sedlmaier B, et al. Translocation of *Helicobacter pylori* CagA into gastric epithelial cells by type IV secretion. *Science* 2000;287:1497–1500.
- [17]. Ohnishi N, Yuasa H, Tanaka S, et al. Transgenic expression of *Helicobacter pylori* CagA induces gastrointestinal and hematopoietic neoplasms in mouse. *Proc Natl Acad Sci U S A* 2008;105: 1003–1008.
- [18]. Higashi H, Tsutsumi R, Fujita A, et al. Biological activity of the *Helicobacter pylori* virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. *Proc Natl Acad Sci U S A* 2002;99:14428–14433.
- [19]. Higashi H, Tsutsumi R, Muto S, et al. SHP-2 tyrosine phosphatase as an intracellular target of *Helicobacter pylori* CagA protein. *Science* 2002;295:683–686.
- [20]. Amieva MR, Vogelmann R, Covacci A, et al. Disruption of the epithelial apical-junctional complex by *Helicobacter pylori* CagA. *Science* 2003;300:1430–1434.